Topical brimonidine reduces collateral damage caused by laser photocoagulation for choroidal neovascularization

Joseph R. Ferencz, Gila Gilady, Orly Harel, Michael Belkin, Ehud I. Assia

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To evaluate the neuroprotective efficacy of brimonidine applied topically to the eyes of patients undergoing laser treatment for extrafoveal or juxtafoveal choroidal neovascularization (CNV). Method: In this prospective, controlled, double-masked pilot study, 20 eyes were randomized to receive either brimonidine 0.2% (study group, 11 eyes) or placebo (matched control group, 9 eyes). Medications were topically applied twice a day during a period of 4-48 h before laser treatment and were continued for 1 month. Results: Two eyes in each group had severe visual loss owing to recurrence of CNV. In the remaining 16 eyes there was a significant improvement in the study group, but no improvement in the control group (P =0.027). Conclusion: Topical brimonidine improves the visual outcome of laser-treated classic extrafoveal or juxtafoveal CNV, possibly by protecting the neuroretina against collateral damage caused by the laser treatment.

Original languageEnglish
Pages (from-to)877-880
Number of pages4
JournalGraefe's Archive for Clinical and Experimental Ophthalmology
Volume243
Issue number9
DOIs
StatePublished - Sep 2005

Keywords

  • Choroidal neovascularization
  • Laserphoto coagulation
  • Neuroprotection

Fingerprint

Dive into the research topics of 'Topical brimonidine reduces collateral damage caused by laser photocoagulation for choroidal neovascularization'. Together they form a unique fingerprint.

Cite this